X4 Pharmaceuticals (XFOR) Assets Average (2018 - 2025)

X4 Pharmaceuticals has reported Assets Average for 8 years, with the latest figure at $227.0 million in Q4 2025.

• For the quarter ending Q4 2025, Assets Average rose 39.86% year-over-year to $227.0 million; the trailing twelve-month figure through Dec 2025 stood at $227.0 million (up 39.86% YoY), and the FY2025 full-year result was $218.5 million, up 48.76% from the prior year.
• Assets Average for Q4 2025 stood at $227.0 million, up from $134.4 million in the prior quarter.
• The five-year high for Assets Average was $227.0 million in Q4 2025, with the low at $90.3 million in Q2 2022.
• Historically, Assets Average has averaged $143.1 million across 5 years, with a median of $139.1 million in 2023.
• Annual changes were most pronounced in 2022 — Assets Average sank 40.32% — and 2023, when it surged 78.32%.
• X4 Pharmaceuticals' Assets Average stood at $118.8 million in 2021, then climbed by 13.17% to $134.5 million in 2022, then increased by 19.17% to $160.3 million in 2023, then rose by 1.27% to $162.3 million in 2024, then soared by 39.86% to $227.0 million in 2025.
• The last three Assets Average figures came in at $227.0 million (Q4 2025), $134.4 million (Q3 2025), and $117.6 million (Q2 2025), per Business Quant data.